Lixisenatide is a GLP-1 receptor agonist that the FDA approved in 2016 for type 2 diabetes, sold in the United States as Adlyxin and in Europe as Lyxumia. It was developed by Zealand Pharma and licensed to Sanofi, which is why older code names like AVE0010 and ZP10 still turn up in the literature. Unusually for an approved drug, it is no longer on the market in either region. Sanofi discontinued U.S. sales effective January 1, 2023, and the European Commission withdrew the Lyxumia marketing authorisation on December 18, 2025, at Sanofi's request. Both moves were described as commercial decisions, not safety actions.
What it is
Lixisenatide belongs to the incretin mimetic class. It is built from exendin-4, a peptide first isolated from the saliva of the Gila monster, the same starting point as exenatide. The molecule is a 44-amino-acid peptide: the C-terminal proline of exendin-4 is removed and six lysine residues are added, with an amide cap at the end. Those changes were made to improve receptor binding and resistance to breakdown.
According to the FDA prescribing information, it was a once-daily subcutaneous injection given before a meal, started at 10 micrograms for 14 days and then raised to a 20-microgram maintenance dose.
How it works
Lixisenatide activates the GLP-1 receptor, which mimics the body's own incretin hormone. The documented effects are glucose-dependent insulin secretion, suppression of glucagon, and slowed gastric emptying. The drug had a comparatively strong effect on gastric emptying, which is why it was positioned mainly against post-meal (postprandial) glucose spikes rather than as a 24-hour agent.
The clinical evidence
Approval rested on the GetGoal program, described by Sanofi as 13 trials in more than 5,000 adults with type 2 diabetes, all of which hit their primary endpoint of HbA1c reduction.
The cardiovascular safety question was settled by the ELIXA trial, published in the New England Journal of Medicine in 2015. It enrolled 6,068 patients with type 2 diabetes and a recent acute coronary event across 49 countries. Lixisenatide was neither better nor worse than placebo on the primary composite of cardiovascular death, heart attack, stroke, or hospitalization for unstable angina. In plain terms: cardiovascular-neutral, which was enough to satisfy the FDA's post-2008 safety requirement but did not give it the heart-protective edge that later GLP-1 drugs claimed.
The more interesting recent chapter is in neurology. The LIXIPARK phase 2 trial, published in NEJM in 2024, randomized 156 people with early Parkinson's disease to lixisenatide or placebo for 12 months. Motor disability, measured on the MDS-UPDRS scale, progressed less in the lixisenatide group, though gastrointestinal side effects such as nausea and vomiting were common. This is a single phase 2 result, not a basis for treating Parkinson's, but it put lixisenatide back into active research as a candidate for repurposing.
Regulatory and WADA status
Lixisenatide was a fully approved prescription drug, not a research chemical, during its time on the market. It is not a controlled substance, and GLP-1 receptor agonists are not on the WADA Prohibited List. Now that authorizations have been withdrawn in the U.S. and EU, it is not legally available as an approved medicine in those markets.
The quality and sourcing angle
Because an approved supply chain no longer exists in these regions, any lixisenatide circulating outside a prescription is, by definition, not a regulated pharmaceutical product. For a 44-amino-acid peptide, the things that matter are identity and purity: that the vial actually contains lixisenatide, at the stated amount, without significant truncated sequences or contaminants. A real certificate of analysis (COA) should show mass spectrometry confirming the correct molecular identity and HPLC purity, ideally tied to the specific batch. Third-party purity and identity testing is the only objective check, and the raters this site aggregates exist to surface exactly that kind of independent data.
Nothing here is medical, dosing, or efficacy advice. Material sold for laboratory use is research use only and not intended for human consumption.